Investments, Funding & Disinvestment

The approval is based on Lilly’s QWINT Phase III clinical programme, which evaluated insulin efsitora alfa-gobe in more than 3,400 adults with T2D across four registration studies.

Kenya’s 2026–2030 Health Products and Technologies Local Manufacturing Strategy targets local production of at least 50 per cent of the country’s essential health products.

Construction was completed in 2013 at a reported cost of nearly Sh200 million (US$1.54 million) through donor funding from the UAE-based Dar Al Ber Society.

The agreement comes as Novo continues to strengthen its position in cardiometabolic medicines, where longer dosing intervals are a growing focus of research and development.

The facility adds domestic manufacturing capacity to the company’s operations as Kenya seeks to strengthen production of medical products within the country.

Anaconda is targeting the large vessel occlusion stroke market, where mechanical thrombectomy is used to remove blood clots from blocked cerebral arteries.

T cell engagers are designed to bring a patient’s T cells into contact with cancer cells, enabling the immune cells to attack the tumour.

ALMA and Malaria No More UK estimate that a 30% reduction in malaria financing could result in 146 million additional cases, almost 400,000 additional deaths and US$37 billion in lost economic output by 2030.

The DIGIT platform is designed as an open and interoperable system that brings campaign planning, management and monitoring into a single interface.

Earendil, a biotechnology company operating in the US and China, will identify and develop bispecific antibody programmes based on target combinations agreed with Genentech.